Covance New Signings Slow In U.S.; Kimbrell Returns To Top At Oread
Executive Summary
The discontinuation of a Lilly/Solvay cardiovascular development program in March is showing up with a six-month delay in Covance operating results with spill-over effects on the image and predictability of the CRO segment.
You may also be interested in...
Covance
Contract research organization has 175 Phase III programs ongoing, firm tells analysts Sept. 16 at the Bear Stearns health care conference in New York (1"The Pink Sheet" Sept. 13, p. 6)
Covance
Contract research organization has 175 Phase III programs ongoing, firm tells analysts Sept. 16 at the Bear Stearns health care conference in New York (1"The Pink Sheet" Sept. 13, p. 6)
Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets
Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: